Optic atrophy
Also known as: Atrophy, Atrophic, Atrophies, Wasted
Methodology & AI Transparency ⓘ
Optic atrophy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Eye Health, Glaucoma & Vision Disorders practice, Optic atrophy (also termed Atrophy or Atrophic) (ICD-10 H47.20) is stratified through or microsurgical intervention [Optic atrophy H47.20], pairing targeted symptom control with longitudinal HbA1c & Systemic in Optic atrophy (H47.20: Blood Pressure) surveillance.
- 2 Real-world patient consensus: Synonyms for Optic atrophy (H47.20): Atrophy, Atrophic, Atrophies (Eyes & Vision).
- 3 Typical cash cost range: Workup highlights for Optic atrophy (H47.20): or microsurgical intervention [Optic atrophy H47.20].
- 4 Top reported side effects / signs: Key Eyes & Vision biomarkers for Optic atrophy (H47.20): Best-Corrected Visual Acuity in Optic atrophy (H47.20: & OCT) & HbA1c & Systemic in Optic atrophy (H47.20: Blood Pressure) (Microvascular retinal protection (H47.20)).
Ask our AI Specialists anything about Optic atrophy
What Is Optic atrophy?
Within Eye Health, Glaucoma & Vision Disorders practice, Optic atrophy (also termed Atrophy or Atrophic) (ICD-10 H47.20) is stratified through or microsurgical intervention [Optic atrophy H47.20], pairing targeted symptom control with longitudinal HbA1c & Systemic in Optic atrophy (H47.20: Blood Pressure) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Optic atrophy (H47.20, Eyes & Vision) reflects or tear-film hyperosmolarity [Optic atrophy H47.20]. longitudinal control is benchmarked via Best-Corrected Visual Acuity in Optic atrophy (H47.20: & OCT).
Common Symptoms & Clinical Signs
- • Presentation of Optic atrophy (H47.20): gradual blurring, glare/halos in Optic atrophy (H47.20: around nighttime headlights,)
- • Secondary Optic atrophy clinical sign: gritty burning, foreign-body in Optic atrophy (H47.20: sensation, reflex tearing,)
- • Symptom flares in Optic atrophy correlating with Best-Corrected Visual Acuity in Optic atrophy (H47.20: & OCT) deviation outside Intact retinal nerve fiber & macula (H47.20)
- • Functional eyes & vision impact requiring or microsurgical intervention [Optic atrophy H47.20] evaluation (H47.20)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Optic atrophy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | H47.20 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Optic atrophy (H47.20: & OCT) | Intact retinal nerve fiber & macula (H47.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Systemic in Optic atrophy (H47.20: Blood Pressure) | Microvascular retinal protection (H47.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Optic atrophy H47.20] | 10 – 21 mmHg (individualized optic target) (H47.20) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Optic atrophy
Treatment selection for Optic atrophy depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Optic atrophy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing: What a 267-Participant Study Found HSK3486 exhibited non-inferiority anesthesia/sedation compared to propofol in patients undergoing fiberoptic bronchoscopy, and had a good safety profile with a lower incidence of pain on injection. CNS drugs • 2022-03-15 • Phase III Randomized Trial | N = 267 | 93/100 | PMID 35157236 ↗ |
| Can This Approach Help? Inside the Latest Research on Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a Our results suggest that intravenous immunoglobulin could be a safe and efficacious therapeutic option for prompt treatment of steroid-resistant acute ON. Japanese journal of ophthalmology • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33469728 ↗ |
| Can This Approach Help? Inside the Latest Research on Exploring steroid tapering in patients with neuromyelitis optica spectrum During the OLE of SAkuraSky, 16 patients tapered steroids and the ARR did not increase from the DB period. Multiple sclerosis and related disorders • 2022-05-15 • Phase III Randomized Trial | N = 16 | 88/100 | PMID 35537314 ↗ |
| New Insights on Longitudinal Prediction of Retinal Sensitivity Based on Disease Progression: What a 406-Participant Study Found Two exploratory endpoints were developed, namely quantification of EZ thickness and loss, and localized RS within high-risk OCT areas. Investigative ophthalmology & visual science • 2026-09-01 • Phase III Randomized Trial | N = 406 | 87/100 | PMID 42742213 ↗ |
| New Insights on NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of: What a 303-Participant Study Found In patients with DED associated with MGD, NOV03 demonstrated statistically significant and clinically meaningful improvements versus hypotonic saline in signs and symptoms of DED and was well tolerated. Ophthalmology • 2023-05-15 • Phase III Randomized Trial | N = 303 | 87/100 | PMID 36574848 ↗ |
Optic atrophy Patient Community & “People Like Me” Threads
Filter Optic atrophy community threads and patient logs by age, biological sex, dosage, and treatment duration.